Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy Males

Inclusion Criteria: * Clinically healthy, male subjects aged 18 to 45 years (inclusive) * Body weight between 40kg and 150kg or a body mass index within the range 15-55kg/m2, calculated using Quetelet's index Exclusion Criteria: * Subjects with history or evidence of hypertrophic or keloid scarring, or with tattoos or previous scars in the area to be biopsied. * Subjects with tattoos or previous scars within 3cm of the area to be incised during the trial. * Afro-Caribbean volunteers, because of their increased susceptibility to hypertrophic and keloid scarring. * Subjects who, on direct questioning and physical examination, have evidence of any past or present clinically significant disease. * Subjects with a chronic or currently active skin disorder, which would adversely affect the healing of the acute wounds or involved the areas to be examined in this trial. * Subjects with a history of clinically significant allergies. * Subjects with any clinically significant abnormality following review of pre-trial laboratory data and physical examination. * Subjects taking, or who had taken, certain prescribed drugs in the 4 weeks before to Day 0 and, in particular, topical or systemic steroids, anti-inflammatory, anti-coagulant, anti-proliferative drugs, and antibiotics. * Subjects who have taken part in a clinical trial within 3 months before admission to this trial, or who are currently participating in a clinical trial, whether an investigational drug was involved or not. * Subjects with any clinical evidence of severe ongoing, or prolonged, depression or mental illness. * Subjects smoking more than 20 cigarettes a day. * Subjects drinking more than 28 units of alcohol per week (1 unit = ½ pint of beer \[285ml\], 25ml of spirits, or 1 glass of wine). * Subjects showing evidence of drug abuse. * Subjects known to have, or to have had, serum hepatitis or who were carriers of the hepatitis B surface antigen (HbsAg) or hepatitis C antibody. * Subjects previously testing positive for HIV antibodies, or who admit to belonging to a high-risk group. * Subjects with pre-existing clinically significant neurological conditions. * Subjects who, in the opinion of an investigator, are not likely to complete the trial for whatever reason.